96 results about "Immune correlates" patented technology

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention belongs to the technical field of biological medicine, and relates to pharmaceutical application of an oxidative phosphorylation inhibitor, in particular to application of the oxidative phosphorylation inhibitor in preparation of an immunomodulatory drug, and the immunomodulatory drug has the advantages that the function damage of newborn myeloid-derived suppressor cells caused by antagonism BCG (bacillus calmette guerin) vaccination is inhibited, and the immunomodulatory effect is improved. The compound is used for preventing or treating neonatal immune-related diseases caused by bacillus calmette guerin vaccine inoculation. The invention finds that the BCG can cause damage to the immunosuppression function of the MDSC of the suckling mouse through up-regulation oxidative phosphorylation, and the negative effect caused by inoculation of the BCG can be reversed by using the OXPHOS inhibitor, so that the immunosuppression function of the MDSC of the suckling mouse is successfully recovered in an in-vivo and in-vitro model, and the immune-related adverse reaction caused by inoculation of the BCG is expected to be improved.

The invention relates to the technical field of chemical toxicology, in particular to an evaluation method for comprehensively analyzing the immune induction effect of a plasticizer by using caenorhabditis elegans, according to the evaluation method, a mother worm breeding mode is changed to replace a lysis solution to synchronize nematodes, experimental interference is reduced, the result accuracy is improved, monitoring indexes are newly increased, intestinal injuries and in-vivo bacterial indexes are increased, and the evaluation method is suitable for comprehensive analysis of the immune induction effect of the plasticizer. The evaluation is more accurate and reliable by combining oxidative stress indexes and performing two-dimensional comprehensive evaluation from an intestinal immune defense line and oxidative stress, and by drawing a multi-index monitoring shape graph, adopting a comprehensive biomarker response index analysis method and associating immune-related representative indexes, the evaluation accuracy is improved. According to the method, the change of each index and the immunity intensity on the caenorhabditis elegans under different exposure conditions are intuitively presented, the immune defense effect of the caenorhabditis elegans under the stress of the plasticizer can be quickly and effectively evaluated without transcriptome and metabonomics, and efficient evaluation is realized.

This invention relates to the field of molecular biology, specifically to the application of miR-193a-5p antagonists in the preparation of drugs for treating immune-associated pneumonia, the sequence of which is shown in SEQ ID NO: 1. This invention experimentally demonstrates for the first time that miR-193a-5p expression is significantly upregulated in an immune-associated pneumonia model, and that the use of its specific antagonist can effectively alleviate pneumonia symptoms; therefore, miR-193a-5p antagonists can be used as active ingredients in the preparation of drugs for treating immune-associated pneumonia caused by immune checkpoint inhibitors.

The invention discloses a PD-L1 monoclonal antibody delivery system as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: coupling amino groups of BPA-PEG9 and a PD-L1 monoclonal antibody through NHS (N-hydroxysuccinimide) esterification to form BPA6-aPDL1; the preparation method comprises the following steps: grafting a glucose derivative maltomimetic acid MA of o-benzene dihydroxyl to a lipid-like amphiphilic molecule PEG (Polyethylene Glycol) (1.5 k-DSPE) through an amido bond to form MA4-PEG (1.5 k-DSPE), namely MA4-PD; then, the BPA6-aPDL1 reacts with the MA4-PD through a boric acid ester bond, and finally, the delivery system MB-aPDL1 is formed. The delivery system not only can successfully deliver the PD-L1 to a tumor site across a blood brain barrier, but also can accurately release the PD-L1 monoclonal antibody, so that the PD-L1 monoclonal antibody is only enriched in a tumor region, the residence time of the antibody is prolonged, the tumor anchoring capability of the antibody is improved, and the occurrence of immune-related adverse events is remarkably reduced.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

Relates to the field of biological medicine, in particular to an antibody specifically binding to IL35 and IL27 and application thereof, and the antibody not only can inhibit binding of IL35 and a receptor thereof, but also can inhibit binding of IL27 and a receptor thereof. Meanwhile, the invention also relates to a nucleic acid sequence for coding the antibody, a carrier and a cell containing the nucleic acid sequence, a pharmaceutical composition containing the antibody, and application of the antibody or the composition containing the antibody to preparation of drugs for treating immune-related diseases and cancers.

The invention discloses a biphenyl compound as shown in a formula (I), and a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound as an active ingredient. The compound is a novel small molecule immunomodulator having an excellent oral absorbable characteristic, and can be used for treating and / or preventing various diseases related to immunity.

A corneal tissue exosome collected after rapid culture of a corneoscleral tissue directly following corneal transplantation is disclosed. The overall manufacturing process is simple, eliminating the procedures of thawing, isolation, and cell culture in conventional cell culture processes, and possesses high production yield and homogeneity, while reducing the generation of biomedical waste. The corneal tissue exosome obtained from the corneoscleral tissue exhibits specific protein expression and possesses potential for treating wound repair, ocular diseases, cancer, and immune-related diseases.

Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

This invention relates to the field of biomedicine, specifically providing a mutant thymosin α1 polypeptide and its applications. The mutant differs from natural thymosin α1 by substituting at least one amino acid at positions 15, 21, and 27, with preferred mutations including D15M, E21W, and E27R. Amino acid substitutions at these sites significantly improve the structural stability and in vivo pharmacokinetic properties of thymosin α1. Experimental results show that, while maintaining the main secondary structural features and overall thermal stability without significant degradation, the mutant improves serum stability and in vivo pharmacokinetic properties, exhibiting superior in vivo half-life and antitumor activity. This invention also provides nucleic acid molecules encoding the mutant, expression vectors, host cells, and pharmaceutical compositions containing the mutant, which can be used for the treatment of tumors, viral infections, and immune-related diseases.

The application provides an animal immune evaluation method based on a Lutzomyia longipalpis infection model, and comprises the following steps: S1, experimental animal preparation and screening; S2, Lutzomyia longipalpis preparation and quality verification; S3, Lutzomyia longipalpis infection of experimental animals; S4, immune related index detection; S5, animal immune function evaluation; and S6, repeatability verification and data summarization. The application realizes systematic and objective evaluation of the effect of immune candidate drugs.

The invention belongs to the technical field of bioengineering, and particularly relates to an engineered IL-6 / IL-12 family subunit combination and application thereof. A beta subunit and an alpha subunit are connected through a flexible polypeptide connecting peptide in a covalent mode to form a stable compound, and the stable compound comprises a subunit combination (p35 / sIL-6R alpha) composed of p35 and soluble IL-6R alpha and a subunit combination (IL-6 / p40) composed of IL-6 and p40. The engineered IL-6 / IL-12 family subunit combination disclosed by the invention has immunomodulatory activity, can be used for regulating immune response, and can be used as a research tool or used for preparing a pharmaceutical composition for treating immune-related diseases.

The invention relates to an InDel molecular marker related to immune traits of Landaise geese and application of the InDel molecular marker, and belongs to the technical field of molecular markers. The InDel molecular marker provided by the invention is located in a full-length sequence of a CNTFR gene as shown in SEQ ID No.1, and insertion of a single base T exists at the 165833rd site. The InDel molecular marker disclosed by the invention can be used for quickly and accurately distinguishing the high / low ratio of heterophilic granulocytes / lymphocytes of the Landaise geese, has the advantages of simplicity and convenience in operation and reliable result, and provides an effective molecular basis for directional breeding of immune-related traits of the Landaise geese.

The present disclosure provides methods of predicting / diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.

Provided are methods for determining if an individual is likely to experience immune-related adverse events (irAEs) if treated for melanoma with a combination of immune checkpoint inhibitors that are an anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) antibody and an anti-programmed death-ligand 1 (PD-1) antibody. The methods include determining differential gene signatures as between individuals who had melanoma and were treated with a combination of a CTLA-4 antibody and an PD-1 antibody but did not experience severe irAEs after the treatment, with the gene signature for an individual who has melanoma but was not treated with an immune checkpoint inhibitor.

Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.

The invention discloses a biphenyl compound as shown in a formula (I), and a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound as an active ingredient. The compound is a novel small molecule immunomodulator having an excellent oral absorbable characteristic, and can be used for treating and / or preventing various diseases related to immunity.

The application discloses a lactococcus lactis GL-1 and application of the lactococcus lactis GL-1 in Apostichopus japonicus breeding, and belongs to the field of aquatic beneficial microorganisms and application technologies thereof. The lactococcus lactis GL-1 is preserved in the China General Microbiological Culture Collection Center on September 16, 2025, and the preservation number is CGMCC No. 35938, and the lactococcus lactis GL-1 is isolated from traditional fermented food doubansauce. The strain can well adapt to different environments, and can be used for preparing an Apostichopus japonicus feed additive. When the number of viable lactococcus lactis GL-1 in the feed is greater than or equal to 1x10 8 CFU / g, the low-salt stress resistance of the Apostichopus japonicus can be significantly enhanced, the survival rate and growth performance are improved, the intestinal flora structure is improved, the colonization of beneficial bacteria is promoted, and immune-related pathways such as the Wnt signal pathway are activated, so that the health level of the Apostichopus japonicus is improved from multiple aspects. A safe and effective microbial solution is provided for solving the low-salt stress problem in the Apostichopus japonicus breeding.

Described herein are techniques for predicting whether a subject will experience an immune-related adverse event (irAE) in response to administration of an immune checkpoint inhibitor (ICI) therapy. In some embodiments, the techniques include: determining a likelihood that the subject will experience the irAE in response to administration of the ICI therapy, the determining comprising: performing: (a) processing clinical data using a first machine learning (ML) model to output a first likelihood that the subject will experience the irAE, (b) processing RNA sequencing data using a second ML model to output a second likelihood that the subject will experience the irAE, and / or (c) processing immune receptor data using a third ML model to output a third likelihood that the subject will experience the irAE; and processing the first, second, and / or third likelihoods using a fourth ML model trained to predict the likelihood that the subject will experience the irAE.

An immune related adverse event marker and a kit. The immune related adverse event marker comprises CD183. The immune related adverse event marker can effectively predict immune related adverse events caused by programmed death receptor 1 antibody / programmed death-ligand antibody therapy, thereby facilitating intervention and treatment of immune related adverse events.

The invention relates to the technical field of disease prognosis and molecular biology, in particular to application of immune-related polygenes in prognosis evaluation of diffuse large B-cell lymphoma. The biomarkers are DES, CHIT1, FGF14, CCR4, CTLA4 and VGF (Vertical Growth Factor). According to the method, core genes related to immunity are screened on the basis of diffuse large B cell lymphoma transcriptome data such as GEO and TCGA, and a multi-gene immune model: RS = (-0.0306) * DES + (-0.4683) * CHIT1 + (1.1418) * FGF14 + (0.1132) * CCR4 + (-0.07) * CTLA4 + (-0.3463) * VGF is constructed; according to the immune polygene immune model, diffuse large B-cell lymphoma patients can be divided into high and low RS groups, the survival prognosis of high-RS people is proved to be obviously lower than that of low-RS people, and the survival prognosis can be used as an independent prognosis index.

The invention discloses a breeding informatization management system based on intelligent agriculture big data, and relates to the technical field of big data management, and the system comprises a breeding file establishment module which is used for taking the specific immune response intensity and stability of a target pathogen as core breeding indexes, screening excellent parents to construct a basic breeding group, and establishing a breeding file; establishing a breeding file containing pedigree, genotype and immune related molecular markers; the immune archive binding module is used for creating a structured immune archive for the individual based on the archive and binding a unique identifier; the immune program formulating module is used for formulating differentiated immune programs according to genetic background layering; the immune program optimization module is used for scanning an identifier at an immune spot to automatically match an optimization scheme; and the multi-index combined seed selection module is used for quantifying the post-immune titer index into a new breeding character and feeding the new breeding character back to the breeding system, so that closed-loop optimization is realized. According to the method, the breeding efficiency, the immune precision and the group disease resistance can be remarkably improved.

Provided are CD73 (also known as ecto-5'-nucleotidase) inhibitor compounds, and compositions and uses thereof for treating and / or preventing CD73-associated diseases, disorders, and conditions, including cancer-associated and immune-associated disorders. CD73 inhibitor compounds include compounds having a structure according to Formula I': (I') and pharmaceutically acceptable esters or salts thereof.

Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response in an individual and / or for treating an immune-related disorder, e.g., cancer, in an individual, including killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen-binding fragment thereof.

The invention discloses metal-based nanoparticles loaded with traditional Chinese medicine as well as a preparation method and application of the metal-based nanoparticles, and relates to the technical field of nano medical materials. The nano-particle is prepared by taking nickel iron zinc aluminum hydroxide as a multi-metal-based core carrier, carrying out PEG modification and cRGD peptide targeted coupling, and loading a traditional Chinese medicine active ingredient curcumin. The preparation is realized through a multi-step chemical coupling and loading process, and the multi-metal carrier can realize responsive structural disintegration and accurate controlled release of curcumin in a tumor weak acid environment. The nanoparticles have active targeting, multi-metal synergistic killing and immune regulation functions, can specifically recognize a triple negative breast cancer cell surface integrin alpha v beta 3 receptor, inhibit tumor cell proliferation, induce apoptosis, regulate BCR, IL-17 and other immune related signal channels, promote immune cell infiltration and remodel a tumor immune microenvironment. The metal-based nano-particles loaded with the traditional Chinese medicine are simple in preparation process, high in production efficiency and suitable for precise treatment of triple negative breast cancer.

The present application discloses PLPC-DB, an ultrapurified phospholipoproteomic composition derived from the supernatant of peripheral blood mononuclear cells (PBMCs). It comprises essential phospholipids, bioactive proteins, regulatory peptides, and intercellular signaling factors. The composition exceeds 99% purity through a multi-stage purification process combining high-speed centrifugation and selective ultrafiltration (1-50 kDa), followed by lyophilization. This process ensures structural stability for ≥24 months and inter-batch variability <2%. PLPC-DB supports reproducibility and molecular integrity in research and diagnostic settings. Key components include phosphatidylcholine and phosphatidylserine for membrane stabilization and intracellular signaling; structural and regulatory lipids for membrane biogenesis and immune-relevant components involved in antigen presentation, cytokine modulation, and membrane-associated signaling. These may include structurally defined molecules compatible with immunological evaluation in experimental and non-therapeutic settings. The composition is formulated for bioaccessible delivery via sublingual, endonasal, transdermal, and injectable routes, and is intended exclusively for non-therapeutic use in experimental and translational models.

Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.

The subject matter described here relates to a method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-IL17RA antibody or antigen binding fragment thereof. The method can also further comprise administering to the subject a therapeutically effective amount of at least one immune checkpoint inhibitor (ICI). The anti-IL17RA antibody or antigen binding fragment thereof treats, reduces, or prevents immune-related adverse events. In some embodiments, the ICI comprises an anti-PD1 antibody, or antigen-binding fragment thereof, comprising the CDRs or variable domains of clones 01, 02, 03, 04, 07, 09, 51, humanized 51, 55, 79, 80, or SEQ ID NOS: 311-312.